1. Definition

5' AMP-activated protein kinase or AMPK or 5' adenoenosine monophosphate-activated protein kinase is an enzyme that plays a role in (AMPK) is in charge of numerous catabolic and anabolic signaling pathways to sustain appropriate intracellular energy homeostasis, largely to activate glucose and fatty acid uptake and oxidation when adenosine triphosphate levels in response to energetic and/or cellular stress. In addition to its conventional roles as an intracellular energy is low. It belongs to a highly conserved eukaryotic protein family and its orthologues are SNF1 in yeast, and SnRK1 in plants. It consists of three proteins (subunits) that together make a functional enzyme, conserved from yeast to humans. It is expressed in a number of tissuesswitch or fuel gauge, emerging research has shown that AMPK is also a redox sensor and modulator, playing pivotal roles in maintaining cardiovascular processes and inhibiting disease progression. Pharmacological reagents, including the liver, brain, and skeletal muscle. In response to binding AMP and ADP, the netstatins, metformin, berberine, polyphenol, and resveratrol, all of which are widely used therapeutics for cardiovascular disorders, appear to deliver their protective/therapeutic effect ofs partially via AMPK activation is stimulation of hepatic fatty acid oxidation, ketogenesis, stimulation of skeletal muscle fatty acid oxidation and glucose uptake, inhibisignaling modulation. The functions of AMPK during health and disease are far from clear. Accumulating studies have demonstrated crosstalk between AMPK and mitochondria, such as AMPK regulation of cholesterol synthesis, lipogenesis, and triglyceride synthesis, inhibition of adipocytmitochondrial homeostasis and mitochondrial dysfunction causing abnormal AMPK activity.

1. Definition

Please lipogenesis, inhibition of adipocyte lipolysis, and modulation of insulin secretion by pancreatic beta-cellrovide an accurate concept or description at the top and briefly highlight the importance or benefits for humans.

2. Introduction

2. Introduction

 Cells constantly coordinate their metabolism to satisfy their energy needs and respond to the use of nutrients. Eukaryotes have developed a highly adaptive complex, the serine/threonine kinase adenosine monophosphate (AMP)-activated protein kinase (AMPK), to sense low cellular adenosine triphosphate (ATP) levels [1]. Under conditions of insufficient energy, AMPK activates upon its binding with AMP or adenosine diphosphate (ADP)^[1] [1]. Once activated, AMPK redirects metabolism toward increased catabolism or decreased anabolism through the phosphorylation of key proteins across multiple pathways, including protein synthesis (e.g., mammalian target of rapamycin complex (1) ^[2][3][2,3], lipid homeostasis (e.g., acetyl coenzyme A carboxylase, ACC) ^[4][5][4,5], glucose metabolism (e.g., phosphofructokinase (2) [6], and mitochondrial homeostasis (e.g., peroxisome proliferator-activated receptor gamma coactivator (PGC) 1 alpha, PGC1α) [7]. Besides, AMPK can adjust intracellular metabolism in a prolonged way by aiming at transcriptional regulators (e.g., forkhead box O₃) [8]. Overall, activated AMPK balances energy levels by raising ATP synthesis and/or reducing ATP consumption. Thanks to its core roles in intracellular metabolism, dysregulation of AMPK is prevalent in obesity, diabetes, cancer, and cardio-metabolic diseases. AMPK is a prospective pharmacological target ^{[9][10][11][12][13][14][15]}[9–15], notably for treating type 2 diabetes ^[16][17][18][16–18].

3. AMPK Structure and Regulation

3. AMPK Structure and Regulation

 3.1. AMPK Structure

AMPK, a heterotrimeric complex, is composed of a catalytic α-subunit and beta (β) and gamma (γ) regulatory subunits [19]. In humans, each subunit has multiple distinct isoforms encoded by different genes: the α-subunit has two isoforms, α1 and α2, encoded by gene PRKAA1 and PRKAA2, respectively [20]; the β-subunit has two isoforms, β1 and β2, encoded by gene PRKAB1 and PRKAB2, respectively [21]; and the γ-subunit has three isoforms, γ1, γ2, and γ3, encoded by gene PRKAG1, PRKAG2, and PRKAG3, respectively [22]. Each AMPK complex is comprised of an α-subunit, a β-subunit, and a γ-subunit, and all possible combinations produce 12 different AMPK complexes [23].

The α-subunit contains the kinase domain and a critical residue (Thr174 in α1-subunit and Thr172 in α2-subunit, hereafter referred to as Thr172) that is phosphorylated by upstream kinases [1]. The α-subunit is essential, and a double knockout (KO) of AMPKα1 and AMPKα2 in mice gives rise to embryonic lethality [24]. The β-subunit includes a carbohydrate-binding module that grants AMPK to bind to glycogen [25]. The γ-subunit allows AMPK to react to changes in the level of AMP, ADP, and ATP, as it includes four tandem cystathionine β synthase motifs that allow AMPK to bind adenine nucleotides [26].

3.2. Regulation of AMPK

3.2.1. AMPK is Activated by AMP/ADP and Inhibited by ATP

AMPK is activated by energy stress and/or cellular stress in response to increased ATP consumption (e.g., exercise, cell proliferation, and anabolism) or decreased ATP production (e.g., low glucose levels, oxidative stress, and hypoxia), which are sensed as low ratios of ATP-to-AMP/ADP. Binding of AMP, and to a lesser degree ADP, to the γ-subunit stimulates AMPK activity via three mechanisms ^[27][28][29][27–29]. First, AMP has been hypothesized to promote the phosphorylation of Thr172 by directly stimulating the activity of the upstream kinase, or by an allosteric mechanism that would render AMPK a suitable substrate for the upstream kinase ^[30][31][32][30–32]. Liver kinase B 1 (LKB1) [32] and calcium/calmodulin-dependent protein kinase kinase (CAMKK) 2 ^[33][34][33,34] can be employed as the two main mammalian upstream molecules that phosphorylate AMPK. Second, AMP protects Thr172 against dephosphorylation by phosphatases ^{[28][35][36][37]}[28,35–37]. Third, AMP causes the allosteric activation of AMPK that has already been phosphorylated on Thr172. Activation loop phosphorylation increases AMPK activity by about 100-fold, while allosteric regulation changes AMPK activity up to tenfold in mammalian cells and about twofold in recombinant, bacterially produced AMPK ^{[26][28][38][39]}[26,28,38,39]. Lastly, allosteric AMPK activation can also occur in non-phosphorylated AMPK, with even higher fold activation than phosphorylated AMPK [40].

3.2.2. Regulation of AMPK by Reactive Oxygen Species (ROS)

ROS are plenty of free radicals and chemically reactive molecules derived from oxygen molecule [41]. Most ROS are generated as byproducts of mitochondrial electron transportation from the reduction of molecular oxygen to produce superoxide [41]. The sequential reduction of superoxide gives rise to the generation of various ROS that includes hydroxyl radical, hydrogen peroxide, and hydroxyl ion [41]. The actions of ROS can be both beneficial and detrimental [41]. The beneficial aspects of ROS at physiological levels are usually related to their effects in cell survival signaling cascades [41]. Excessive production of ROS, usually termed oxidative stress, are caused by increased production and/or insufficient presence of endogenous antioxidants [41]. Oxidative stress is considered detrimental because of its damage to fats, deoxyribonucleic acid, and proteins in a cell, which can lead to numerous diseases such as diabetes, cancer, neurodegenerative disease, and cardiovascular disease (CVD) [41]. Recent lines of evidence have demonstrated AMPK responsiveness to imbalanced redox status, thus bringing new insights into the networks of redox-stimulated signals upstream of AMPK (Table 1) ^[42][43][42–51]. For instance, Trolox, a vitamin E analog and antioxidant, reduces cellular ROS levels ^[44][51]. The addition of Trolox to mouse embryonic fibroblasts (MEFs) resulted in basal AMPK activity reduction, as evidenced by the decreased phosphor-AMPKα at Thr172 ^[44][51].

Table 1. The type of reactive oxygen species (ROS) that activates adenosine monophosphate-activated protein kinase (AMPK). ATP, adenosine triphosphate; ADP, adenosine diphosphate; BAEC, bovine aortic endothelial cell; MEF, mouse embryonic fibroblast; VSMC, vascular smooth muscle cell; HUVEC, human umbilical vein endothelial cell; NOS, nitric oxide synthase; LKB1, liver kinase B 1; CAMKK2, calcium/calmodulin-dependent protein kinase kinase; PDK1, pyruvate dehydrogenase kinase 1; CRAC, calcium release-activated calcium.

Hydrogen Peroxide and AMPK Activation

AMPK is activated by hydrogen peroxide in various cell types. In H4IIEC3 cells, exogenous hydrogen peroxide transiently increased the level of phosphor-AMPK by LKB1 signaling, while exogenous hydrogen peroxide promoted AMPK phosphorylation in HeLa cells by CaMKK signaling [42]. Thromboxane A2 receptor (TPr) agonists increased the expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX), thereby promoting the formation of superoxide in vascular smooth muscle cells (VSMCs) [52]. Exposure of cultured rat VSMCs to either TPr agonists or hydrogen peroxide led to AMPK activation in a time- and dose-dependent manner, as supported by the increased phosphor-AMPK at Thr172 and its downstream enzyme phosphor-ACC at Ser79 [61]. TPr agonists-activated AMPK was mediated by hydrogen peroxide, as demonstrated by the results showing overexpression of catalase (CAT) abolished Tpr agonists-induced AMPK activation [61]. In the meantime, LKB1 was activated by either TPr agonists or hydrogen peroxide [61]. Further, dominant negative mutation of LKB1 abolished both TPr agonists and hydrogen peroxide-stimulated AMPK activation, which suggested that hydrogen peroxide mediated TPr-triggered AMPK activation by LKB1 signaling [61]. These results collectively suggest that AMPK activation by hydrogen peroxide occurs through activation of either LKB1 or CaMKK, depending on the cell type.

ROS, in excess, can provoke energy stress and metabolic failure by direct oxidizing and inactivating enzymes of the tricarboxylic acid cycle, electron transport chain (ETC), and glycolysis ^[62][63][62,63]. It is well established that the ROS-induced energy stress strongly activates AMPK, which is likely the main mechanism of ROS-mediated AMPK activation. For instance, exposure of exogenous hydrogen peroxide to C2C12 cells led to a dose-dependent increase in AMPK activity by decreasing the ATP-to-ADP ratio [44]. Similarly, in NIH-3T3 cells, exogenous hydrogen peroxide transiently activated AMPK in a dose-dependent manner, which was associated with an increased AMP-to-ATP ratio [45]. Further, using HEK293 cells expressing AMPKγ2 R531G, an AMP-insensitive AMPK complex, AMPK cannot be activated by hydrogen peroxide [46]. These findings suggest that the target for hydrogen peroxide may not be AMPK itself, but components of the ETC, leading to a secondary effect on AMPK through changes to ADP, AMP, and ATP.

Alternatively, some studies showed that ROS directly activated AMPK independent of changes in ADP, AMP, and ATP. Exogenous or glucose oxidase-generated hydrogen peroxide induced direct S-glutathionylation on the AMPKα subunit at Cys299 and Cys304, which contributes to AMPK activation [48]. However, this view has been challenged with the fact showing that replacement of redox-sensitive cysteine residues with insensitive alanine residues does not affect hydrogen peroxide-induced AMPK activation [44,53].

Reactive Nitrogen Species (RNS) and AMPK Activation

Nitric oxide (NO) is produced by nitric oxide synthase (NOS) from l-arginine in the cell. RNS is produced beginning with the interaction between NO and superoxide to generate peroxynitrite. The sequential reaction of peroxynitrite with other molecules generates additional species of RNS, including dinitrogen trioxide and nitrogen dioxide, as well as other types of chemically reactive molecules. ROS broadly include NO and its derivative RNS, both of which have been implicated in AMPK activation.

Compared with wild-type (WT) mice, neuronal NOS KO (nNOS^−/−) mice showed both reduction of stroke damage and AMPK activation, which suggests a possible link between NO and AMPK activity in the context of stroke [47]. In the studies using cultured bovine aortic endothelial cells (BAECs), peroxynitrite significantly activated AMPK, as supported by increased phosphor-AMPK at Thr172 as well as increased phosphor-ACC, a downstream target of AMPK, at Ser79 [54]. In endothelial cells (ECs), studies showed that NO endogenously activated AMPK via elevating Ca²⁺ levels by the activation of soluble guanylyl cyclase [55]. Further, NO-triggered Ca²⁺ increase causes AMPK activation through CaMKK2 signaling [55].

Exposure of ECs to chemically synthesized peroxynitrite acutely and significantly increased phosphorylation of AMPK and its downstream target ACC without affecting cellular AMP [56]. Hypoxia-reoxygenation (H/R) increased both AMPK and ACC phosphorylation in cultured BAECs, which was prevented by either inhibition of NOS or overexpression of SOD, suggesting a role of peroxynitrite formed during H/R [56]. These results indicate that H/R via peroxynitrite activates AMPK in ECs [56]. It is debatable whether LKB1 participates in AMPK activation under hypoxia condition. Some studies showed that LKB1^−/− MEFs under hypoxia for 30 min could not increase ACC phosphorylation [57], while LKB1^−/− MEFs under hypoxia for 2 h activated AMPK through CaMKK2 [58], indicating that LKB1-induced AMPK activation occurs in a context-dependent manner.

NO- and RNS-dependent activation of AMPK is probably related to the ability of NO and RNS to suppress mitochondrial ATP production by modulating the ETC [64]. In fact, NO at nanomolar concentration can form a nitrosyl–heme complex to selectively and reversibly inhibit cytochrome c oxidase [65]. RNS at higher concentration can induce cysteine S-nitrosylation or tyrosine nitration in almost all the complexes of mitochondrial ETC ^[66][67][66,67].

3.2.3. AMPK is a Key Modulator for Maintaining Redox Homeostasis

AMPK is not only a senor of redox signal, but also plays an anti-oxidative role once activated (Table 2). AMPK can diminish the superoxide production derived from either mitochondria or nicotinamide adenine dinucleotide phosphate oxidase (NOX). Further, AMPK also can suppress oxidative stress by upregulation of antioxidant gene expression.

Table 2. Activation of AMPK suppresses oxidative stress. AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; WT, wild-type; SD, Sprague Dawley; SOD, superoxide dismutase; CAT, catalase; UCP, uncoupling protein; NOX, nicotinamide adenine dinucleotide phosphate oxidase; PGC, peroxisome proliferator-activated receptor gamma coactivator.

AMPK Suppresses ROS

Mitochondrial ROS is increased by many atherosclerosis stimuli, including hyperglycemia, triglycerides, and oxidized low-density lipoprotein (oxLDL) ^[74][75][76][74–76]. One study reported that pharmacological activation of AMPK by either salicylate or 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) regulated mitochondrial morphology and ameliorated endothelial dysfunction through suppression of mitochondrial ROS-associated endoplasmic reticulum (ER) stress and the subsequent activation of the thioredoxin-interacting protein-associated NACHT, LRR and PYD domains-containing protein 3 inflammasome [68]. Miglitol protected against endothelial cell damage from oxidative stress via inhibition of apoptosis and mitochondrial superoxide production by activation of the AMPK–eNOS axis [69].

Under basal conditions, in addition to mitochondrial ETC, NOX is another source of ROS production in ECs [77]. Inflammation-triggered endothelium activation generally gives rise to a large scale of ROS production that is mainly attributed to membrane-bound and/or cytosolic enzymes such as NOX [78]. Further, NOX-induced ROS production can enhance ROS production from other sources such as mitochondrial ETC and xanthine oxidase (XO) ^[77][79][80][77,79,80]. Analysis of AMPKα2 KO ECs and AMPK α2-silenced human umbilical vein endothelial cells (HUVECs) indicated that suppression of AMPK could increase NOX expression, NOX-mediated superoxide production, 26S proteasome activity, inhibitory subunit of nuclear factor kappa Bα degradation, and nuclear translocation of nuclear factor kappa B [70]. These studies indicated that AMPKα2 functions as a physiological suppressor of NOX and ROS production in ECs, in which way AMPK maintains the nonatherogenic and non-inflammatory phenotype of ECs [70].

AMPK Increases Antioxidant Potentials

The continuously produced ROS from mitochondrial ETC can be eliminated by antioxidant systems. It has been demonstrated that AMPK activation limited mitochondrial ROS generation in MEFs through PGC1α-dependent antioxidant response [51]. In this study, the potent AMPK activator A-769662 promoted an AMPK-dependent increase in several antioxidant genes, including CAT, superoxide dismutase (SOD)1, SOD2, and uncoupling protein 2 (UCP2). Moreover, a study using control or PGC1α-deficient MEFs with A-769662 showed that antioxidant gene expression was dependent on PGC1α expression. Similarly, in HUVECs, metformin normalized hyperglycemia-induced mitochondrial ROS production by inducing manganese SOD and promoting mitochondrial biogenesis through the activation of the AMPK–PGC1α pathway [71]. AMPK activation by either metformin or AICAR in HUVECs could suppress superoxide production by increasing the expression of the antioxidant gene UCP2 [72]. Further, AMPK activation by metformin lowered the grade of acute lung injury and acute respiratory distress syndrome via the inhibition of oxidative stress by upregulating SOD1 and PGC1α, thus providing potential value for treating such conditions in clinic [73].

4. Perspectives

4. Perspectives

 It is well-accepted that AMPK activation plays protective roles across diverse CVDs. AMPK has emerged as a guardian of mitochondria because almost all mitochondrial insults can activate AMPK. However, the interplay within the AMPK–mitochondrial axis during the initiation and progression of CVDs is poorly investigated. Limited evidence has focused on mitochondrial dynamics, mitochondrial biogenesis, and mitophagy, the three common functions of mitochondria that have been studied by cell biologists. Far beyond our current knowledge are the structural and functional changes to mitochondria that may be amplified under disease conditions. Therefore, it would be advantageous for investigators in the field of CVDs to focus on observing, defining, and clarifying novel characteristics and properties of mitochondria, thus contributing to both cell biology and advancing disease treatments.